⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TARA News
Protara Therapeutics, Inc. Common Stock
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
globenewswire.com
TARA
Form 8-K
sec.gov
TARA
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
globenewswire.com
TARA
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
globenewswire.com
TARA
Form 8-K
sec.gov
PRTO
TARA
Form 8-K
sec.gov
TARA
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
globenewswire.com
TARA
Form 8-K
sec.gov
TARA
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
globenewswire.com
TARA
Protara Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
TARA